A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
Status:
Completed
Trial end date:
2018-03-14
Target enrollment:
Participant gender:
Summary
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical
study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of
SUVN-911 or placebo will be orally administered to healthy male subjects to evaluate the
safety, tolerability, and pharmacokinetic profile.